The use of palliative chemotherapy in pediatric oncology patients: A national survey of pediatric oncologists
Authors:
- Tammy I. KangTKTammy I. Kang
- Kari HexemKHKari Hexem
- Russell LocalioRLRussell Localio
- Richard AplencRARichard Aplenc
- 28 September 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (1) , 88-94
Abstract
Background Many children continue receiving chemotherapy after there is no realistic hope for cure. One factor that influences parental decisions to pursue medical therapies is physician preference. To date, no studies have described pediatric oncologists' perspectives and practices regarding palliative chemotherapy (PC). Procedure We surveyed via email pediatric oncologists practicing in the U.S who are members of the Children's Oncology Group to achieve the following objectives: (1) Describe pediatric oncologists treatment considerations regarding the use of PC. (2) Assess treatment considerations that influenced pediatric oncologists' therapy recommendations for their most recent patient receiving PC. There were 422 participants (40.8%) who completed the survey. Results The most important factors considered by pediatric oncologists when prescribing PC were the toxicity of the chemotherapy (4.90 mean SD = 0.36 utilizing 5 point scale with 1 = not important to 5 = very important), the preferences of the family (4.57; SD = 0.60), and the potential to decrease symptoms arising from tumor burden (4.42; SD = 0.65). These treatment considerations were not as important when PC was prescribed for their most recent patient. Similarly, the chief aims in prescribing PC were not achieved for recent patients receiving PC. For their most recent patient who received PC, 40.8% believe this treatment was primarily for parental wishes. Conclusion According to 80.2% of pediatric oncologists completing the survey, some patients receive chemotherapy beyond medical benefit and 40.8% of these oncologists have prescribed PC for the purpose of parental wishes to a recent patient. The chief aims in prescribing palliative chemotherapy were not achieved for recent patients. Pediatr Blood Cancer 2013; 60: 88–94.Keywords
This publication has 27 references indexed in Scilit:
- Quality of care at the end of life in children with cancerJournal of Paediatrics and Child Health, 2009
- Parents’ Views of Cancer-Directed Therapy for Children With No Realistic Chance for CureJournal of Clinical Oncology, 2008
- Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From CancerJournal of Clinical Oncology, 2006
- Parent and Physician Perspectives on Quality of Care at the End of Life in Children With CancerJournal of Clinical Oncology, 2005
- Temozolomide in resistant or relapsed pediatric solid tumorsPediatric Blood & Cancer, 2005
- Cancer-Related Deaths in Children and AdolescentsJournal of Palliative Medicine, 2005
- Oral etoposide for recurrent/progressive sarcomas of childhoodPediatric Blood & Cancer, 2003
- Understanding of Prognosis Among Parents of Children Who Died of CancerJAMA, 2000
- Symptoms and Suffering at the End of Life in Children with CancerNew England Journal of Medicine, 2000
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal of Cancer, 1997